|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our meta-analysis showed that the FAS -670 A/G polymorphism was associated with the risk of autoimmune diseases (GG vs. GA: OR=1.079, 95% CI=1.004-1.160, P=0.038), especially in Caucasians (GG vs. GA: OR=1.12, 95% CI=1.03-1.23, P=0.012), Asians (G vs. A: OR=0.89, 95% CI=0.83-0.96, P=0.002), systemic lupus erythematosus (SLE) (G vs. A: OR=0.85, 95% CI=0.77-0.94, P=0.001), multiple sclerosis (MS) (GG+GA vs. AA: OR=0.83, 95% CI=0.70-0.99, P=0.043), systemic sclerosis (SSc) (GG vs. GA: OR=1.20, 95% CI=1.07-1.36, P=0.003) and Hashimoto's thyroiditis (HT) (G vs. A: OR=1.45, 95% CI=1.10-1.90, P=0.008); the FAS -1377 G/A polymorphism was associated with the risk of autoimmune diseases (A vs. G: OR=1.11, 95% CI=1.03-1.20, P=0.008), especially in Asians (A vs. G: OR=1.15, 95% CI=1.05-1.25, P=0.002) and high quality studies (A vs. G: OR=1.14, 95% CI=1.05-1.24, P=0.002).
|
31840751 |
2020 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The effect of spironolactone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis.
|
31520539 |
2020 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Hashimoto's thyroiditis (HT) is an autoimmune disorder caused by the interaction between genes and environmental triggers.
|
30924423 |
2020 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with Hashimoto's Thyroiditis (HT) or Graves' Disease (GD) were individually compared to a control group of patients with early stage malignancy or goiter.
|
31651072 |
2020 |
|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among all ATEs, Graves' disease (GD) was the most represented [63% of cases, 95% confidence interval (CI) 52-74%], followed by Hashimoto thyroiditis (15%, 95% CI 10-22%).
|
31452116 |
2020 |
|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Autoimmune thyroid disease, including Graves' disease (GD) and Hashimoto's thyroiditis (HT), is one of the most common endocrine diseases.
|
31557082 |
2020 |
|
Hypothyroidism
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hypothyroidism is associated with higher testosterone levels in postmenopausal women with Hashimoto's thyroiditis.
|
31681972 |
2020 |
|
Hypothyroidism
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto's thyroiditis is the most common cause of hypothyroidism.
|
31614366 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto's thyroiditis (HT) is an autoimmune disease characterized by chronic inflammation of thyroid gland.
|
31669586 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Available evidence on the relation between vitamin D status and Hashimoto's thyroiditis (HT) remains inconsistent.
|
31089869 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto's thyroiditis (HT) is an autoimmune disorder caused by the interaction between genes and environmental triggers.
|
30924423 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have comprehensively evaluated an immunologic response to food antigens, mediated by immunoglobulin G (IgG) antibodies, on clinical aspects of Hashimoto's thyroiditis (HT).
|
30265836 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto's thyroiditis (HT) is often associated with rheumatic disorders (arthritis, etc.), but many HT patients report non-specific rheumatic signs and symptoms in the absence of clinically evident rheumatic diseases.
|
31301020 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hashimoto's thyroiditis, also referred to as autoimmune thyroiditis, is characterized by sexual dimorphism, suggesting an important role of sex hormones in its development.
|
31520539 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the prevalence of Hashimoto thyroiditis (HT) in primary thyroid lymphoma (PTL) and whether it differs between mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma (DLBCL).
|
31584614 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with Hashimoto's Thyroiditis (HT) or Graves' Disease (GD) were individually compared to a control group of patients with early stage malignancy or goiter.
|
31651072 |
2020 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
All of these showed that MSCs can regulate Th17/Treg interactions in a rat Hashimoto's thyroiditis (HT) model system.
|
31793369 |
2020 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis showed that the FAS -670 A/G polymorphism was associated with the risk of autoimmune diseases (GG vs. GA: OR=1.079, 95% CI=1.004-1.160, P=0.038), especially in Caucasians (GG vs. GA: OR=1.12, 95% CI=1.03-1.23, P=0.012), Asians (G vs. A: OR=0.89, 95% CI=0.83-0.96, P=0.002), systemic lupus erythematosus (SLE) (G vs. A: OR=0.85, 95% CI=0.77-0.94, P=0.001), multiple sclerosis (MS) (GG+GA vs. AA: OR=0.83, 95% CI=0.70-0.99, P=0.043), systemic sclerosis (SSc) (GG vs. GA: OR=1.20, 95% CI=1.07-1.36, P=0.003) and Hashimoto's thyroiditis (HT) (G vs. A: OR=1.45, 95% CI=1.10-1.90, P=0.008); the FAS -1377 G/A polymorphism was associated with the risk of autoimmune diseases (A vs. G: OR=1.11, 95% CI=1.03-1.20, P=0.008), especially in Asians (A vs. G: OR=1.15, 95% CI=1.05-1.25, P=0.002) and high quality studies (A vs. G: OR=1.14, 95% CI=1.05-1.24, P=0.002).
|
31840751 |
2020 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Autoimmune thyroid diseases (AITDs), i.e., Graves' disease (GD) and Hashimoto thyroiditis (HT), are the most prevalent organ-specific autoimmune diseases, but their pathogenesis is still incompletely understood.
|
31182340 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A systematic literature research of the last 15 years, according to EQUATOR statement, was carried out through MEDLINE via PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) Embase, CINAHL, Cochrane Library, based on the following keywords: (autoimmune thyroid disease OR Hashimoto thyroiditis OR Grave's disease) AND (autoimmune comorbidities OR extra-thyroidal autoimmune disorders) AND (children OR adolescents OR pediatrics) AND (celiac disease OR type 1 diabetes mellitus OR arthropathies OR cutaneous diseases) AND (Turner syndrome OR Down syndrome).
|
31354636 |
2019 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Atorvastatin potentiates the effect of selenomethionine on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis.
|
30354702 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Seventeen patients developed ADs, including myasthenia gravis (MG) (n=13), Hashimoto's thyroiditis (n=4), Sjogren's syndrome (n=1), rheumatoid arthritis (n=1), pemphigus (n=1), and Evans syndrome (n=1).
|
31179102 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The Effect of Selenomethionine on Thyroid Autoimmunity in Euthyroid Men With Hashimoto Thyroiditis and Testosterone Deficiency.
|
31106856 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
It was inferred that therapy should be recommended for children with underlying Hashimoto's thyroiditis and progressive deterioration of thyroid status over time, particularly in the cases with goiter and hypothyroid symptoms and in those with associated Turner syndrome or Down's syndrome and/or other autoimmune diseases.
|
30858827 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that add-on VA-therapy in cancer patients with preexisting autoimmune diseases as Hashimoto's thyroiditis, psoriasis, ulcerative colitis, Grave's disease, and some rheumatic diseases is safe.
|
30808274 |
2019 |